Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.

  2. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of

  3. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. … Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties.

    Synonyms: d-ibuprotenProducts: Eu-Med 200 mg Schmerztabletten
  4. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    to as the Democratic Republic of the Congo) and Sudan. … Ervebo consists of an envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain) fused into a vesicular stomatitis virus (VSV) backbone.

    Synonyms: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP
  5. Drug

    Setoperone

    go.drugbank.com/drugs/DB20520
    Experimental

    Setoperone has a monoisotopic molecular weight of 401.16 Da. … Setoperone is a small molecule drug. The usage of the INN stem '-perone' in the name indicates that Setoperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative.

    Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of Chemicals
  6. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. … [L64055] It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination and proteasomal degradation of the transcription factors Aiolos and Ikaros

  7. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    of cytokine release syndrome (CRS), a serious condition associated with the use of immunotherapy. … [L43887,L43892] A phase I clinical study (NCT02290951) showed that in heavily pre-treated patients with B-cell non-Hodgkin lymphoma, odronextamab elicited a durable response with a manageable safety

  8. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. … Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).

  9. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives. … Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B

  10. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion. … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering